


### **Mapping viral hepatitis**

- CHB prevalence, care, treatment; CHC prevalence and treatment; liver cancer
  - By PHN and SA3
- Collation of multiple data sources:
  - For prevalence: population-specific seroprevalence (CHB) and notifications (CHC)
  - For care and treatment: Medicare MBS and PBS
- Cascades of care by region
- High priority areas and populations
- Track progress

#### 1. Trends in hepatitis C treatment



26

0.0%

5.0%

10.0%

2016 uptake (%) 2017 uptake (%)

15.0%

20.0%

25.0%


30.0%

35.0%

40.0%


Darling Downs and West Moreton 24 Murrumbidgee 29 Northern Territory 30 Western Queensland 31

#### 1. Trends in hepatitis C treatment




Treatment utpake and rank 2016 and 2017, by PHN


### 1. Trends in hepatitis C treatment




### 2. Gaps in the CHB monitoring cascade




## 3. Disparities between monitoring and prescribing



## 3. Disparities between monitoring and prescribing



# 4. Representation of work from priority regions




#### Acknowledgements

- Epidemiology team, The Doherty Institute
- ASHM, partners in Mapping Project
- Department of Health, Australian Government
- Department of Human Services, Australian Government
- National Notifiable Diseases Surveillance System
- WHO CC VH Research Advisory Group
- Simon Graham, Praveena Gunaratnam
- Individuals who provided review and data
  - Kelly Hosking and Geoff Stewart, Simon Graham, Josh Hanson

### **Explore the portal:**

#### https://ashm.org.au/programs/Viral-Hepatitis-Mapping-Project/



The Peter Doherty Institute for Infection and Immunity A joint venture between The University of Melbourne and The Royal Melbourne Hospital